PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Summary

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.

Timeline

Start

2024-09-20

Primary completion

2027-09-05

Completion

2027-10-10

Drugs

Indications

No indication recorded.